#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians managing patients with cannabis use disorder now have potential pharmacological options, as evidence suggests diabetes medications may reduce addictive behaviors across multiple substances including cannabis. This finding is particularly relevant for patients with comorbid diabetes and substance use disorders, where a single medication could address both conditions while reducing relapse risk. Understanding these cross-addiction effects allows providers to make more informed treatment decisions and counsel patients on emerging therapeutic alternatives beyond traditional addiction medications.
A large-scale study examining glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of diabetes medications including semaglutide and tirzepatide, suggests these agents may reduce addictive behaviors across multiple substances including cannabis, cocaine, nicotine, and opioids. The findings indicate that GLP-1 RAs may work through shared neurobiological pathways involved in reward and addiction, offering a potential pharmacological intervention beyond traditional addiction management strategies. This discovery is particularly relevant for clinicians treating patients with comorbid diabetes and substance use disorders, a population at high risk for poor health outcomes and treatment non-adherence. The research suggests that metabolic medications could provide dual benefit by controlling glucose levels while simultaneously reducing cravings and addictive behaviors, though further mechanistic studies and clinical trials are needed to establish efficacy and optimal dosing protocols. For cannabis-using patients specifically, this finding may eventually expand treatment options for cannabis use disorder, which currently has limited pharmacological interventions. Clinicians should consider discussing GLP-1 RA therapy with diabetic patients who also struggle with cannabis or other substance use, while recognizing that additional evidence is needed before these agents can be routinely recommended as addiction treatments.
“What this research tells us is that GLP-1 agonists may work upstream on the reward circuitry itself rather than just treating the behavioral manifestation of addiction, which means we need to start thinking about cannabis use disorder not as a moral failing but as a treatable metabolic and neurochemical condition alongside obesity and diabetes.”
💊 Recent evidence suggesting that GLP-1 receptor agonists (commonly prescribed for type 2 diabetes) may reduce cravings and substance use across multiple addiction types, including cannabis, is intriguing but requires cautious interpretation in clinical practice. The mechanisms underlying these potential benefits remain incompletely understood, and it remains unclear whether observed associations reflect direct pharmacological effects, weight loss, improved metabolic health, or patient selection bias—particularly since individuals with both diabetes and addiction may represent a distinct population with different prognostic factors. Healthcare providers should recognize that these findings do not yet support prescribing GLP-1 agonists as an addiction treatment outside of appropriate diabetes indications, and patients may harbor unrealistic expectations about the drugs’ anti-addictive properties based on media coverage. Nevertheless, the observation warrants further investigation through rigorous clinical trials, and in the interim, clinicians managing patients with concurrent diabetes and cannabis use disorder should
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: